onc201
Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors
Neuro Oncol. 2021 PMID: 32830856
ONC201 Publications
onc201
A Bayesian machine learning approach for drug target identification using diverse data types
Nat Commun. 2019 PMID: 31745082
onc201
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
Neuro Oncol. 2020 PMID: 31702782
onc201
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
J Neurooncol. 2019 PMID: 31456142
onc201
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
J Immunother Cancer. 2019 PMID: 31118108
onc201
Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism
Clin Cancer Res. 2019 PMID: 30559168
onc201
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
J Clin Invest. 2018 PMID: 29533922
onc201
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget
Oncotarget. 2017 PMID: 29108308
onc201
First-in-Human clinical trial of oral ONC201 in patients with refractory solid tumors
Clin Cancer Res. 2017 PMID: 28331050
onc201
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Sci Signal. 2016 PMID: 26884599